Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043)

A Multicenter, Open-Label, Noncomparative Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Acetate in Children With Documented Candida or Aspergillus Infections

This study is an open label, noncomparative study using an investigational agent for the treatment of documented Candida or Aspergillus infections in pediatric patients (ages 3 months-17 years).

• Children, 3 months through 17 years of age,
• with esophageal candidiasis or
• invasive candidiasis or
• children requiring salvage treatment of invasive aspergillosis.